Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940900 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
A Phase 3 study, sponsored by Ophthotech Corporation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 627
- Enrollment target
NCT01940900: Clinical Trial Phase 3 study, sponsored by Ophthotech Corporation.
NCT01940900 is a Phase 3 study that was terminated before completion, run by Ophthotech Corporation. The registered enrollment target is 627 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01940900, a Phase 3 study, was terminated before completion, sponsored by Ophthotech Corporation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 627 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Primary Outcome
The primary efficacy endpoint is the mean change in visual acuity (ETDRS letters) from baseline to the month 12 visit. Higher ETDRS letters represents higher vision and a higher change in ETDRS letters represents better functioning.
Interventions
- DRUG ranibizumab
- DRUG E10030
- DRUG E10030 sham intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Why NCT01940900 stopped before completion
NCT01940900 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 3 interventions - of which ranibizumab is the first listed.
NCT01940900 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01940900 about?
NCT01940900 is a clinical study titled "A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy". The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT01940900?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 627 participants. The study started on 2013-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01940900?
The interventions under investigation include: ranibizumab (DRUG), E10030 (DRUG), E10030 sham intravitreal injection (DRUG).
Who is sponsoring clinical trial NCT01940900?
This trial is sponsored by Ophthotech Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01940900's enrollment target sits among peer trials
627 586th of 2000 higher than 1,415 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia